SWOG 1206: A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer
CTO - 8648
Cancer - Lung
Principal Investigator: Ding Wang, MD, PhD
This study is evaluating the dose of Veliparib added to chemotherapy with Carboplatin and Paclitaxel for unresectable stage III non-small cell lung cancer.
- Males and females at least 18 years of age.
- Patients must have histologically or cytologically-proven unresectable Stage IIIB, non-small cell lung cancer (adenocarcinoma, bronchioloalveolar cell carcinoma, large cell carcinoma, squamous cell carcinoma, or mixed).
- Patients must have measureable or non-measurable disease documented by CT, MRI, or PET/CT.